Document
IPR2023-00724, No. 2532 Exhibit - EX2532 Synjardy and Synjardy XR Prescribing Information rev Oct 2023 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2532 Exhibit - EX2532 Synjardy and Synjardy XR Prescribing Information rev Oct 2023 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2360 Exhibit - EX2360 Quianzon, C CL and Cheick, IE, History of current non insulin medications for diabetes mellitus, J Community Hosp Intern Med Perspect 2012 Oct 15...
Cite Document
IPR2023-00724, No. 2360 Exhibit - EX2360 Quianzon, C CL and Cheick, IE, History of current non insulin medications for diabetes mellitus, J Community Hosp Intern Med Perspect 2012 Oct 15 23 Doi 1034
+ More Snippets
Document
IPR2023-00724, No. 2070 Exhibit - EX2070 NCT03144271, “Dose Escalation of Single Subcutaneous Doses of NNC 0113 0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacod...
Cite Document
IPR2023-00724, No. 2070 Exhibit - EX2070 NCT03144271, “Dose Escalation of Single Subcutaneous Doses of NNC 0113 0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy
+ More Snippets
Document
IPR2023-00724, No. 2468 Exhibit - EX2468 Stegluromet Prescribing Information rev Dec 2017 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2468 Exhibit - EX2468 Stegluromet Prescribing Information rev Dec 2017 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2451 Exhibit - EX2451 US Food Drug Administration, DrugsFDA, Glyxambi (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2451 Exhibit - EX2451 US Food Drug Administration, DrugsFDA, Glyxambi (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2394 Exhibit - EX2394 Mansfield, C, et al, Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain An Online Discrete Choice Expe...
Cite Document
IPR2023-00724, No. 2394 Exhibit - EX2394 Mansfield, C, et al, Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain An Online Discrete Choice Experiment Sur
+ More Snippets
Document
IPR2023-00724, No. 2018 Exhibit - EX2018 Transcript of December 29, 2023 Deposition of John Bantle, MD (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2018 Exhibit - EX2018 Transcript of December 29, 2023 Deposition of John Bantle, MD (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2393 Exhibit - EX2393 DiBonaventura, Md, et al, Multinational Internet based survey of patient preference for newer oral or injectable Type 2 diabetes medication, Patient P...
Cite Document
IPR2023-00724, No. 2393 Exhibit - EX2393 DiBonaventura, Md, et al, Multinational Internet based survey of patient preference for newer oral or injectable Type 2 diabetes medication, Patient Prefer A
+ More Snippets
Document
IPR2023-00724, No. 2094 Exhibit - EX2094 Eckel, RH and Blaha, MJ, Cardiometabolic Medicine A Call for a New Subspecialty Training Track in Internal Medicine, Am J Med, 1327788 790 2019...
Cite Document
IPR2023-00724, No. 2094 Exhibit - EX2094 Eckel, RH and Blaha, MJ, Cardiometabolic Medicine A Call for a New Subspecialty Training Track in Internal Medicine, Am J Med, 1327788 790 2019 (P.T.A.B. Jan
+ More Snippets
Document
IPR2023-00724, No. 2103 Exhibit - EX2103 Marx, N, et al, GLP 1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes, Circulation, 14618...
Cite Document
IPR2023-00724, No. 2103 Exhibit - EX2103 Marx, N, et al, GLP 1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes, Circulation, 1461882 1894
+ More Snippets
Document
IPR2023-00724, No. 2426 Exhibit - EX2426 Nesina® Prescribing Information rev Dec 2016 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2426 Exhibit - EX2426 Nesina® Prescribing Information rev Dec 2016 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2395 Exhibit - EX2395 Byetta® Prescribing Information rev Feb 2015 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2395 Exhibit - EX2395 Byetta® Prescribing Information rev Feb 2015 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2109 Exhibit - EX2109 Sattar, N, et al, Novel Diabetes Drugs and the Cardiovascular Specialist, J Am Coll Cardiol, 69 2646 2656 2017 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2109 Exhibit - EX2109 Sattar, N, et al, Novel Diabetes Drugs and the Cardiovascular Specialist, J Am Coll Cardiol, 69 2646 2656 2017 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2529 Exhibit - EX2529 Eli Lilly Co, Income Statements for Year Ending 2019 to 2022, httpsinvestorlillycomfinancial informationfundamentalsincome statement, last visited ...
Cite Document
IPR2023-00724, No. 2529 Exhibit - EX2529 Eli Lilly Co, Income Statements for Year Ending 2019 to 2022, httpsinvestorlillycomfinancial informationfundamentalsincome statement, last visited Jan 14, 2
+ More Snippets
Document
IPR2023-00724, No. 2361 Exhibit - EX2361 National Institute of Diabetes and Digestive and Kidney Diseases, “Low Blood Glucose Hypoglycemia,” httpswwwniddknihgovhealth informationdiabe...
Cite Document
IPR2023-00724, No. 2361 Exhibit - EX2361 National Institute of Diabetes and Digestive and Kidney Diseases, “Low Blood Glucose Hypoglycemia,” httpswwwniddknihgovhealth informationdiabetesoverviewprev
+ More Snippets